Teva's Olanzapine LAI Shows Strong Stabilization Rates Ahead of FDA Decision
Event summary
- Teva presented post hoc data from the SOLARIS Phase 3 trial showing 56% of participants stabilized on TEV-'749, with 21% achieving remission after six months.
- Switching analyses demonstrated predictable olanzapine exposures when transitioning from oral or short-acting injections to TEV-'749.
- FDA decision on TEV-'749 expected in Q4 2026, with EMA application already accepted in May 2026.
The big picture
Teva's TEV-'749 represents a strategic push into long-acting injectables for schizophrenia, addressing adherence challenges in a market dominated by daily oral treatments. The positive SOLARIS trial data positions TEV-'749 as a potential differentiator ahead of the FDA decision, while Medincell's SteadyTeq™ technology underscores Teva's commitment to innovative neuroscience solutions. The focus on stabilization and remission rates highlights the unmet need for treatments that reduce relapse risk in schizophrenia patients.
What we're watching
- Regulatory Approval
- Whether the FDA will approve TEV-'749 in Q4 2026, potentially expanding Teva's long-acting injectable franchise.
- Market Differentiation
- How TEV-'749's once-monthly subcutaneous formulation will compete against existing oral and injectable olanzapine treatments.
- Commercialization Strategy
- The pace at which Teva can transition patients from oral olanzapine to TEV-'749, leveraging the switching data presented.
Related topics